Bb Biotech AG BB BIOTECH ORD SHS
Bb Biotech AG BB BIOTECH ORD SHS/ CH0038389992 /
0JYO
|
24/05/2024 16:54:25
|
Chg.
-
|
Volume |
Bid17:40:03 |
Ask17:40:03 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
40.73CHF
|
-
|
637
Turnover: 23,400.11 |
-Bid Size: - |
-Ask Size: - |
2.07 bill.CHF |
5.34% |
- |
Business description
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
Management board & Supervisory board
| CEO |
| - |
| Management board |
| - |
| Supervisory board |
| Dr. Thomas von Planta, Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Camilla Soenderby, Prof. Dr. Mads Krogsgaard Thomsen |
Company data
| Name: |
BB Biotech AG |
| Address: |
Schwertstraße 6,CH-8200 Schaffhausen/Schweiz |
| Phone: |
+41-52-624-0845 |
| Fax: |
- |
| E-mail: |
info@bbbiotech.com
|
| Internet: |
www.bbbiotech.com |
| Industry: |
Financial |
| Sector: |
Specialty Finance |
| Sub sector: |
Diversified Financial |
| End of financial year: |
31/12 |
| Free Float: |
100.00% |
| IPO date: |
10/12/1997 |
Investor relations
| Name: |
Dr. Silvia Siegfried-Schanz |
| IR phone: |
+41-44-267-7266 |
| IR Fax: |
- |
| IR e-mail: |
ssc@bellevue.ch
|
Main Shareholders
| FreeFloat |
|
96.47% |
| Lazard Asset Management LLC, New York, USA |
|
3.53% |
